Search Results
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
and information and are subject to change without notice.References 1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M.,
More news about: Servier Pharmaceuticals
May 31, 2026, 16:30 ET Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
Taylor Morrison to pay a termination fee; and (xvii) other risks set forth under the heading "Risk Factors," of Taylor Morrison's Annual Report on Form 10-K for the year ended December 31, 2025 and in Taylor Morrison's subsequent filings with the Securities and Exchange Commission ("SEC"). You should not rely
More news about: Taylor Morrison Home Corporation
May 31, 2026, 11:00 ET United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
scalable PET/CT platform provides clinical flexibility through multiple PET axial fields of views, with the 24 cm, 30 cm, 53 cm, 71 cm, and 107 cm all FDA 510(k) cleared. The family includes the uMI Panvivo Mobile, designed to bring molecular imaging closer to patients, wherever they need it. Its compact, patient
More news about: United Imaging Healthcare Co., Ltd.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
onset of VTEs was 84 days (range: 6 to 777).Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO™ or
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking
More news about: Eli Lilly and Company
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is
More news about: GRAIL, Inc.
May 30, 2026, 18:36 ET STLA Deadline: STLA Investors with Losses in Excess of $100K Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit
multimedia:https://www.prnewswire.com/news-releases/stla-deadline-stla-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-stellantis-nv-securities-fraud-lawsuit-302785953.htmlSOURCE
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 17:31 ET SES AI Corporation Deadline: SES Investors with Losses in Excess of $100K Have Opportunity to Lead SES AI Corporation Securities Fraud Lawsuit Filed by The Rosen Law Firm
multimedia:https://www.prnewswire.com/news-releases/ses-ai-corporation-deadline-ses-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-ses-ai-corporation-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302786093.htmlSOURCE
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 17:07 ET NUAI Deadline: NUAI Investors with Losses in Excess of $100K Have Opportunity to Lead New Era Energy & Digital, Inc. Securities Fraud Lawsuit
multimedia:https://www.prnewswire.com/news-releases/nuai-deadline-nuai-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-new-era-energy--digital-inc-securities-fraud-lawsuit-302785947.htmlSOURCE
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
轉移性乳癌中觀察到的不同抗藥性機制，並且在不論 ESR1 突變狀態如何的情況下，提升患者治療成果。 研究包含六種治療方案，分別評估埃拉司群與 CDK4/6 抑制劑（帕博西尼 (palbociclib)、阿貝馬西利 (abemaciclib) 及瑞博西利 (ribociclib)），以及 PI3K/AKT/mTOR 訊號傳導途徑抑制劑（依維莫司 (everolimus)、阿培利西 (alpelisib) 和卡帕塞替尼 (capivasertib)）聯合治療的療效。2026 年美國臨床腫瘤學會週年大會上公佈的 ELEVATE 研究結果（摘要 1098）[1]
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 14:58 ET Cyient Enters Agreement to Acquire TAO Digital
industries, spanning design-to-aftermarket across products, plants, and networks. We work with 300+ global customers across 30 countries and are supported by 14K+ associates. Recognized among the Top 10 pure-play global engineering services providers, we reported $658M in annual revenue for FY26. We serve industries
More news about: Cyient
May 30, 2026, 14:53 ET IGEL pořádá roadshow „Now & Next Workspace & Endpoint Security Summits" v pěti evropských městech
havárii (BCDR).Program se také bude zabývat tím, jak mohou organizace v kritických odvětvích využít centrálně řízenou strategii pro koncová zařízení k omezení expozice lokálních dat, zmírnění tlaku na obnovovací cykly a posílení provozní kontinuity.Připravované zastávky turné IGEL Now &
More news about: IGEL
May 30, 2026, 14:43 ET Cyient Enters Agreement to Acquire TAO Digital
industries, spanning design-to-aftermarket across products, plants, and networks. We work with 300+ global customers across 30 countries and are supported by 14K+ associates. Recognized among the Top 10 pure-play global engineering services providers, we reported $658M in annual revenue for FY26. We serve industries
More news about: Cyient
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 14:30 ET Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.Investor Contact:Steven M. HarasymTel: +1
More news about: Precigen, Inc.
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
regimi terapeutici che valutano elacestrant in combinazione con inibitori di CDK4/6 (palbociclib, abemaciclib e ribociclib) e con inibitori della via PI3K/AKT/mTOR (everolimus, alpelisib e capivasertib).I risultati dello studio ELEVATE presentati all'ASCO 2026 (abstract 1098) [1] includono
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
de tratamento que avaliam o elacestranto em combinação com inibidores de CDK4/6 (palbociclibe, abemaciclibe e ribociclibe) e com inibidores da via PI3K/AKT/mTOR (everolimo, alpelisibe e capivasertibe).Resultados do estudo ELEVATE apresentados na ASCO 2026 (resumo 1098) [1] incluem dados
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
de tratamiento que evalúan el elacestrant combinado con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de ELEVATE que se presentaron en la ASCO 2026 (resumen 1098)[1] incluyen
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 08:00 ET The Rosen Law Firm, P.A. Continues to Remind Investors of the Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
Counsel for Defendants Jonathan K. YoungwoodJanet A. GochmanSimpson Thacher & Bartlett LLP425 Lexington AvenueNew York, NY 10017 If
More news about: The Rosen Law Firm, P.A.
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is
More news about: GRAIL, Inc.
May 30, 2026, 07:39 ET AMZFAST、Computex 2026において次世代ディスプレイポートフォリオを発表
TVを内蔵し、電源を入れた瞬間にストリーミングサービスやアプリへ即座にアクセス可能最新の第4世代OLEDパネル技術を採用したゲーミングディスプレイ：真の黒（トゥルーブラック）と無限のコントラスト比を実現し、ゲーミングとエンターテインメントの双方における視覚体験を再定義「Curved」シリーズにおける大幅なスペックの飛躍 - 5K2K超高解像度、UWQHD/240Hz、および4K/160Hzモデルが、解像度、リフレッシュレート、および色精度の新たなベンチマークを確立し、ゲーマーとクリエイターの双方に優れた没入感を提供業界をリードする380Hzおよび400Hzのリフレッシュレートに達する新しいesports特化型ディスプレイ - 競技における反応速度と精度を新たな高みへと引き上げ
More news about: AMZFAST
May 30, 2026, 06:52 ET Menarini Group、ASCO2026でER+/HER2-転移性乳がん対象エラセストラント・カピバセルチブ併用ELEVATE試験の新データを発表
ELEVATE試験は、ESR1変異の有無にかかわらず、ER+/HER2-転移性乳がん（mBC）で認められる様々な耐性メカニズムを克服し、患者転帰を改善するため、エラセストラントとの併用治療選択肢の安全性および有効性を評価する目的でデザインされました。本試験は、エラセストラントとCDK4/6阻害薬（パルボシクリブ、アベマシクリブ、リボシクリブ）およびPI3K/AKT/mTOR経路阻害薬（エベロリムス、アルペリシブ、カピバセルチブ）との併用を評価する6つの治療レジメンで構成されています。ASCO2026で報告されるELEV
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 19:13 ET IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
trials, particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the Securities and Exchange Commission in January 30, 2026, that the trial was exhibiting "strong operational progress" and the planned interim
More news about: THE ROSEN LAW FIRM, P. A.
May 29, 2026, 17:31 ET Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.Investors:
More news about: Actinium Pharmaceuticals, Inc.